Braasch Biotech Names New Members To Board Of Directors

GARRETSON, SD--(Marketwired - November 11, 2013) - Braasch Biotech LLC, a pioneering biopharmaceutical company, today announces the addition of two new members to its current Board of Directors. Dr. David Probst and Mr. Layne Asay will help guide Braasch Biotech with a focus on enhancement of current operations, developing new markets and maximizing profitability.

“We are pleased to have David and Layne join our Board of Directors and value the expertise that they bring to Braasch Biotech,” stated Jeralyn Haffer, CEO and Board Chairman. “This addition to our Board ensures that our company will fully leverage the worldwide business opportunities being created by our proven technologies and expanding patent portfolio. We look forward to the paradigm shifts the products of Braasch Biotech will make in the world.”

David Probst brings over 30 years of professional experience in the education and private sectors in the areas of Leadership, Strategic Planning, Business Development and Staff Development and Training. He currently is online faculty at Peru State University and Phoenix University, as well as President of Probst and Associates. Previously he was on faculty at Clarkson College and held senior administration positions in the Nebraska Public School System. Dr. Probst holds a Bachelor’s and Master’s degree in Education and Psychology from the University of Nebraska-Omaha and Ed.D from the University of Nebraska-Lincoln in Administration Curriculum and Instruction.

Layne Asay has over 25 years of extensive sales, global marketing and management experience in the animal health field. He has worked across the entire spectrum of food animal species and product classes. Most recently he was the Director of Marketing, Poultry and Hatchery Services at Ceva Animal Health and Director of Strategic Marking at Alpharma. Previously he was with American Cyanamid and Elanco Animal Health. While at American Cyanamid he helped transition the animal health business through a series of acquisitions that included acquisitions by American Home Products, Roche, Alpharma and King Pharmaceuticals. Mr. Asay holds a Master’s degree in Agribusiness Management and Bachelor’s in Animal Science from Brigham Young University.

About Braasch Biotech
Braasch Biotech is pioneering a new field of metabolic and therapeutic vaccine approaches utilizing Somatovac® technologies. The company has received numerous US and International patents for vaccine usage in human obesity and livestock productivity. Braasch Biotech is a privately held biopharmaceutical company with corporate offices in South Dakota.

For more information on Braasch Biotech, please email info@braaschbiotech.com or visit www.braaschbiotech.com.

Digg this Bookmark with del.icio.us Add to Newsvine

Technorati: vaccines obesity livestock productivity health therapeutics